×
About 4,198 results

SARS-COV2 Pandemic Serosurvey in a Rare Disease Population
https://clinicaltrials.gov/ct2/show/NCT04609085

Jan 21st, 2022 - It has been demonstrated that respiratory virus outbreaks and pandemics, such as influenza, SARS, MERS, and now the newly emerged SARS-COV2 virus, have a major impact on morbidity and mortality worldwide, as well as having devastating global economic and societal impact. During these outbreaks it is critical to gain a rapid understanding of the exposures and immunity in the general population. ...

UPMC OPTIMISE-C19 Trial, a COVID-19 Study
https://clinicaltrials.gov/ct2/show/NCT04790786

Jan 21st, 2022 - While COVID-19 vaccination will reduce COVID-19-related morbidity and mortality, the learned immune response may vary between individuals. This means interventions such as monoclonal antibodies (mAB) will still be needed to prevent progression of COVID-19 illness. Monoclonal antibodies seek to mimic or enhance the natural immune system response against a pathogen and are often used in the care ...

A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
https://clinicaltrials.gov/ct2/show/NCT04537806

Jan 21st, 2022 - The purpose of this study is to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.

NCI COVID-19 in Cancer Patients, NCCAPS Study
https://clinicaltrials.gov/ct2/show/NCT04387656

Jan 21st, 2022 - PRIMARY OBJECTIVES: I. Characterize patient factors, such as pre-existing comorbidities, cancer type and treatment, and demographic factors, associated with short- and long-term outcomes of coronavirus 2019 (COVID-19), including symptoms, severity, and fatality, in adult and pediatric cancer patients undergoing treatment. II. Describe cancer treatment modifications made in response to COVID-19 ...

Study in COvid-19 Patients With iveRmectin (CORVETTE-01)
https://clinicaltrials.gov/ct2/show/NCT04703205

Jan 20th, 2022 - Treatment of mild COVID-19 is basically performed at an outpatient clinic, then when the symptom and clinical findings exacerbate to a moderate level, patients are admitted. There is no standard treatment for mild cases. This study will investigate whether ivermectin administration suppresses the replication of SARS-CoV-2 in mild to moderate COVID-19 by investigating the negative rate of SARS-C...

Photodynamic Therapy for COVID-19 Prevention
https://clinicaltrials.gov/ct2/show/NCT05184205

Jan 20th, 2022 - There is a wide variety of people who test positive for SARS-CoV-2. This is directly dependent upon their exposure to the virus, their age and any medical comorbidities that they may have. At this time, it is not possible to predict who will have an adequate immune response to avoid getting COVID-19. Since this remains unpredictable a universal approach to treating SARS-CoV-2 positive patients ...

Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients
https://clinicaltrials.gov/ct2/show/NCT05163613

Jan 20th, 2022 - Study aim: The purpose of this study was to evaluate the efficacy of low-frequency magnetic field in the hybrid treatment of COVID-19 patients, i.e., including magnetostimulation in the standard treatment. Material and methods: The study was conducted on patients aged 39 to 80 years, of both sexes affected by COVID-19. The study subjects were recruited at the Covid Unit of the Military Medical ...

ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
https://clinicaltrials.gov/ct2/show/NCT05198063

Jan 20th, 2022 - This study adopts an open experimental design. It is planned to screen 300 subjects of 18 years old and above who have completed the basic immunization of recombinant novel coronavirus vaccine (CHO cells), to evaluate the immunogenicity and safety of the booster immunization of 6 months (window period ± 1 month) after the basic immunization. Immunogenicity observation: the geometric mean titer ...

Anti-SARS Cov-2 T Cell Infusions for COVID 19
https://clinicaltrials.gov/ct2/show/NCT04401410

Jan 19th, 2022 - The first part of this study is to identify the maximum tolerated dose (MTD) of allogeneic SARS-CoV2-specific T cells (SARS-CoVSTs) for patients with COVID19 with high risk of progression to mechanical ventilation. The 3 dose levels (DL) are: DL1: 1x10^7 cells (flat dose) DL2: 2x10^7 cells (flat dose) DL3: 4x10^7 cells (flat dose) Enrollment to the dose escalation phase will be staggered. The f...

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
https://clinicaltrials.gov/ct2/show/NCT04476953

Jan 19th, 2022 - To determine if Fisetin treatment can prevent deterioration of oxygenation status as measured by S/F ratio: SpO2/ FiO2, as well as prevent deterioration in physical function (frailty) and hyper-inflammation, other measures of oxygenation status (progression to supplemental oxygen requirement, assisted breathing/ ventilation), and progression from mild/ moderate to severe/ critical proven SARS-C...

Identifying Risks of COVID-19 Outbreaks in Work Settings and the Implications for Control Measures
https://clinicaltrials.gov/ct2/show/NCT05197673

Jan 19th, 2022 - Objectives: To identify core and cross-time workplace hazards and worker's exposure prevention profile towards outbreaks in three non-healthcare work settings; to evaluate effectiveness of a theory-based educational programme on improving attitude to vaccination and virus testing in workplace; to longitudinally compare attitude of willingness to vaccination, testing of SARS-CoV-2 and changes of...

AAA Rupture Risk Assessment in COVID-19 Pandemic
https://clinicaltrials.gov/ct2/show/NCT05197543

Jan 19th, 2022 - The acute phase of the COVID-19 pandemic requires a redefinition of healthcare system to increase the number of available intensive care units for COVID-19 patients. This leads to the postponing of elective surgeries including the treatment of abdominal aortic aneurysm (AAA). The probabilistic rupture risk index (PRRI) recently showed its advantage over the diameter criterion in AAA rupture ris...

Face Masks to Reduce SARS-CoV-2 Infections in Bangladesh
https://clinicaltrials.gov/ct2/show/NCT05197725

Jan 19th, 2022 - Detailed Description: This study intends to answer the following research questions: Can mask distribution and mask promotion at homes, mosques, markets and other public areas successfully change community mask-wearing norms to increase mask-wearing, even years into a pandemic? Can community mask-wearing reduce SARS-CoV-2 infections (both symptomatic and asymptomatic)? Is increased prevalence o...

Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
https://clinicaltrials.gov/ct2/show/NCT05196477

Jan 19th, 2022 - This was a multicentre retrospective cohort study of patients admitted to hospitals in various Russian Federation cities with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid (RNA) laboratory test for the treatment of severe acute respiratory syndrome. The study used information from primary medical documentation of COVID-19 patients who had underwent diagnosti...

A Bridging Study of FB2001 in Healthy Subjects
https://clinicaltrials.gov/ct2/show/NCT05197179

Jan 19th, 2022 - Coronaviruses belong to the genus of coronavirus of the family coronaviruses. The viruses of the coronavirus genus are positive-sense single-stranded RNA viruses with envelopes, which are approximately 80-160 nm in diameter. Their genetic material is the largest among all RNA viruses and can infect both humans and animals. Coronaviruses can cause respiratory, intestinal, hepatic, and nervous sy...

Zooming in on Cerebral Abnormalities in Severely Affected COVID-19 Patients
https://clinicaltrials.gov/ct2/show/NCT05197296

Jan 19th, 2022 - Brain injury is one of the complications in COVID-19 intensive care unit (ICU) survivors, though the precise underlying mechanism is unclear. It is likely caused by a combination of prolonged hypoxia, a massive systemic inflammatory response, direct infection of the brain and small vessel vasculitis in combination with widespread hypercoagulopathy and thrombosis. Using novel MRI techniques, blo...

Evaluation of a COVID-19 Rapid Diagnostic Test in ER Departments in Mexico: a Multi-center Study
https://clinicaltrials.gov/ct2/show/NCT04894760

Jan 19th, 2022 - This study aims to analyze the usefulness of rapid tests, especially: a) as a diagnostic test in people attending care for nonspecific, respiratory symptoms, in emergency services of referral hospitals b) as a diagnostic test in contacts of known patients. c) as a diagnostic test to differentiate influenza from COVID-19 in the circumstance of an overlap of both viruses in the community. d) In t...

Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection
https://clinicaltrials.gov/ct2/show/NCT04624997

Jan 18th, 2022 - In December 2019, an outbreak of pneumonia caused by a new coronavirus occurred in Wuhan and spread rapidly throughout China, with the evolution towards a global pandemic. Originally called new coronavirus 2019 (2019-nCoV), the virus was later officially named Coronavirus 2 of Severe Acute Respiratory Syndrome (SARS-CoV-2) by WHO. On 30 January 2020, WHO declared the SARS-CoV-2 outbreak as a pu...

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 1)
https://clinicaltrials.gov/ct2/show/NCT05194033

Jan 18th, 2022 - In selected communities or assigned clinical trial institutions, participants who had completed two doses of SARS-CoV-2 vaccination will be invited in this study. Informed consent form will give to potential participants with well explained of trial contents during baseline. Participants who gave their signed informed consent form will be blocked randomized in a 1:1 ratio to intervention group ...

TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
https://clinicaltrials.gov/ct2/show/NCT05195060

Jan 18th, 2022 - 2. INTRODUCTION AND RATIONALE New SARS-CoV-2 specific monoclonal antibodiestherapies From the beginning of the worldwide pandemic till now no effective specific anti- SARS-CoV-2 treatment was available1,2. In June 2021 the use of SARS-CoV-2 monoclonal antibodies as early treatment for SARS-CoV-2 infected individuals became available in the Netherlands after an emergency use authorisation of the...